Figure 3. Up-regulated circRNAs with in vitro efficacy in preclinical AML-related cellular systems. A) Circular RNAs targeting transmembrane receptors and secreted proteins. B) Circular RNAs involved in signaling and up-regulating transcription factors. ALG3: α-1,3 mannosyltransferase; AMPK: AMP-activated protein kinase; circATP1B1: circ Na, K ATPase β subunit1; circDLEU2: circ deleted in lymphocytic leukemia 2; circKCNQ5: circ potassium voltage-gated KQT member; circKEL: Circ KELL blood group locus; circPAN3: circ pan domain 3; circNFIX: circ nuclear factor IX; circPTK2: circ protein tyrosine kinase 2; circPVT1: circ plasmacytoma variant translocation 1; circRAD18: circ E3 ubiquitin-protein ligase 18; circRNF220: circ ring finger 220; COX2: cyclooxygenase 2; CXCR4: CXC motif chemokine receptor 4; EIF5A2: eukaryotic translation initiation factor 5A2; FOXM1: forkhead box M1; GRB10: growth factor receptor bound protein 10; IGF-1R: insulin growth factor 1 receptor; IRES2: immediate early response 2; LRG1: leucine rich α2-glycoprotein; miR: microRNA; mTOR: mammalian target of rapamycin; NR: not resolved; MYSMI: deubiquitinase MYSMI; RAB10: ras-related protein 10; PRKACB: cAMP-dependent protein kinase A catalytic subunit β; S100A7A: S100 protein S100A7; SOX4 and SOX12: sex-determining region 4 or 12 related high mobility group; TSPAN3: tetraspanin 3; ULK1: unc 51-like kinase; TRIM31: tripartite motif 31; XIAP: X-linked inhibitor of apoptosis.